Form 10-Q · Quarterly report
Textron 10-Q, filed Jul 28, 2026
- Filed
- CIK
- 0000217346
- Accession no.
- 0000217346-26-000036
Summary
Textron reported second-quarter 2026 revenues of $3.83 billion, up 3% year over year, with gross margin falling 100 basis points to 17.8% on lower Bell segment margins, while first-half revenues rose 7% to $7.52 billion. Textron said it submitted refund requests for IEEPA tariffs during the second quarter of 2026 and has begun receiving refunds after the U.S. Supreme Court ruled on February 20, 2026 that such tariffs were not authorized by the statute, and that it has not experienced a material adverse impact from tariffs to date.
Key points
- Q2 2026 revenues rose 3% to $3.83 billion and first-half revenues rose 7% to $7.52 billion compared with 2025.
- Gross margin fell 100 basis points to 17.8%, which Textron attributed primarily to lower margin at the Bell segment.
- Total backlog was $18.9 billion at July 4, 2026, versus $18.8 billion at January 3, 2026.
- Textron eliminated the Textron eAviation reporting segment effective January 4, 2026, moving a significant part of it including Pipistrel into Textron Aviation and its military manned and unmanned products into Textron Systems.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Business Environment Since early 2025, the United States has made various changes to its trade policy resulting in new or higher tariffs on goods imported from numerous countries. We are principally a North American manufacturer and 69% of our 2025 revenues were generated in the U.S. Many of our aircraft materials and components qualify under the rules of the United States-Mexico-Canada Agreement for preferential treatment on tariffs imposed by the U.S. on imports from Canada and Mexico. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.